Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
- 26 April 2021
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 2 (4) , 302-318
Abstract
B-cell maturation antigen (BCMA)–specific chimeric antigen receptor (CAR) T cells have substantial therapeutic potential in multiple myeloma (MM), but most patients eventually relapse. Determinants of response and mechanisms of resistance are most likely multifactorial and include MM-related factors, premanufacturing T-cell characteristics, CAR T-cell–related features, and several components of the immunosuppressive microenvironment. Efforts to improve the potency and safety of CAR T-cell therapy include optimizing CAR design, combinatorial approaches to enhance persistence and activity, treatment of less heavily pretreated patients, and dual-antigen targeting to prevent antigen escape. We expect that these rationally designed strategies will contribute to further improvement in the clinical outcome of patients with MM.Significance: Although BCMA-specific CAR T-cell therapies are highly effective in heavily pretreated patients with MM, there has been, until now, no indication of a plateau in the survival curves. In this review, we provide an overview of the determinants of response and the mechanisms that contribute to the development of treatment failure after initial remission (acquired resistance). A better understanding of these mechanisms, underlying lack of disease response, and acquired resistance may lead to further improvements in the effectiveness of CAR T-cell therapy.Keywords
This publication has 147 references indexed in Scilit:
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myelomaBlood, 2013
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaLeukemia, 2013
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple MyelomaClinical Cancer Research, 2013
- Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cellsBlood, 2011
- Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With BortezomibClinical Lymphoma Myeloma and Leukemia, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cellsProceedings of the National Academy of Sciences, 2005
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumorsProceedings of the National Academy of Sciences, 2001